SoftOx Solutions AS: Softox Solutions secures committed financing facility

Softox Solutions AS ("SoftOx") is pleased to announce that it today hasenteredinto a financing facility with the global investment fund Long StateInvestmentsLimited ("Long State") for a total commitment of NOK 50 million over a24-monthperiod, with the option to extend the facility to NOK 80 million over 36months.

Under the facility, Long State has granted SoftOx an equity line of credit,allowing SoftOx to call funds against the issuance of new shares on a flexiblebasis in accordance with market conditions. SoftOx is not obligated to utilizethe facility and will only access the program subject to prevailing marketconditions, retaining full discretion over the timing, minimum subscriptionprice, and amount of each drawdown.

The share placements will be executed by the board under the boardauthorizationgranted by the general meeting June 27 2025. The subscription price for theshares will be a function of the VWAP of SoftOx's shares during a pricingperiod, upon which pricing and volume will be calculated and announced.

"This facility puts SoftOx in a position of maximum financial flexibility,ensuring we can access capital to support our priorities while maintainingcontrol over both timing and pricing," said Ingrid Juven, Chief FinancialOfficer of SoftOx.

As commission for the guarantee facility, Long State shall receive animplementation fee of up to 30 million shares in SoftOx, plus a market-basedcash consideration equal to a percentage of the actual invested amount, and aone-time grant of 60 million warrants with the right to subscribe for 60millionshares in SoftOx at a subscription price (strike) of NOK 0,1506. The warrantcompensation will be resolved by a forthcoming extraordinary general meeting,or, if preferred by SoftOx, its cash-value equivalent at their time of grant.

"We see this as a relevant, flexible, and effective tool under the currentmarket conditions for emerging life science companies," said Ulrik Spork,Chairman of SoftOx. "It gives us important certainty around capital formationaswe move into the execution phase of our clinical trials, ensuring we haveresources available when we need them."

The facility effectively serves as a robust guarantee for SoftOx to conductshare placements up to the committed amount, providing a reliable source ofcapital. The facility provides SoftOx with an opportunity to tailor capitalraising according to its needs, while ensuring a stable financial platform forfurther growth and development. The agreement does not restrict SoftOx fromseeking other equity or strategic financing alternatives and may be terminatedby SoftOx at any time without penalty.

For further information, please contact:

Ulrik Spork, COB SoftOx Solutions AS, +45 31 38 83 87 Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165

Mail: ir@soft-ox.com

About SoftOx Solutions AS: SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical companylisted on Euronext Growth Oslo. The company is developing highly effectivepan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. Thetechnology is based on extensive research and development in partnership withleading Nordic research institutes.

About Longstate; Long State is an investment company that focuses on growth sectors. It investsin areas including biotechnology, energy, mining, and technology, and has aworldwide presence, with investments in Australia, Canada, the EEA, the UK,andthe US.

https://newsweb.oslobors.no/message/652927